Addiction_Medication_Table.docx.pdfAddiction_Medication_Table.docx.pdf!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!######################################
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!#######################Addiction_Medication_Table.docx.pdfAddiction_Medication_Table.docx.pdf!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Addiction_Medication_Table.docx.pdf!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!#######################Addiction_Medication_Table.docx.pdfAddiction_Medicat
Darah Cummins
Drug Name Indication Half-life Notable Side Effects (link Initial Dosing
Neurotransmitter(s) Affected (T1/2), to NT or affected brain Considerations
Target Symptoms Metabolis circuit) Specific lifespan
m (CYP 450 considerations (age,
enzyme) pregnancy, breastfeeding)
Buprenorphine Indication: Half-life: Headache, Initial dosing:
(Subutex) Maintenance 24-42 constipation, Day 1: 8 mg
treatment of opioid hours nausea Day 2: 12-16 mg
dependence CYP450: Oral hypoesthesia, Days 3-7: Increase in
Maintenance CYP3A4 glossodynia increments of 4 mg,
treatment of opioid Orthostatic maximum 32 mg
dependence in hypotension Considerations:
patients who have Implant specific: Use with caution
achieved and insertion site pain, in elderly and
sustainced prolonged pruritis, erythema those with cardiac
clinical stability on Respiratory impairment
low-to-moderate depression May be
doses of a Hepatotoxicity preferable to
transmucosal methadone in
buprenorphine- pregnant women
containing product Neonatal
Moderate to severe withdrawal may
opioid use disorder occur
in patients who have Drug is found in
initiated treatment breast milk,
with a transmucosal recommended to
buprenorphine- DC drug or bottle
containing product, feed
followed by dose Safety and
adjustment for a efficacy has not
minimum of 7 days been established
Neurotransmitters: for children and
Mu opioid receptor adolescents
partial agonist
Addiction_Medication_Table.docx.pdfAddiction_Medication_Table.docx.pdf!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!######################################
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!#######################Addiction_Medication_Table.docx.pdfAddiction_Medication_Table.docx.pdf!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Addiction_Medication_Table.docx.pdf!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!#######################Addiction_Medication_Table.docx.pdfAddiction_Medicat
,Addiction_Medication_Table.docx.pdfAddiction_Medication_Table.docx.pdf!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!######################################
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!#######################Addiction_Medication_Table.docx.pdfAddiction_Medication_Table.docx.pdf!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Addiction_Medication_Table.docx.pdf!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!#######################Addiction_Medication_Table.docx.pdfAddiction_Medicat
Darah Cummins
Antagonist at the
kappa opioid
receptor
Target symptoms:
Opioid dependence
Buprenorphine/Naloxone Indication: Half-life: Headache, Initial dosing:
(Suboxone, Zubsolv, Induction of Suboxone: constipation, Bunavail:
Bunavail) treatment for opoid 24-42 nausea Day 1: induction
dependence hours Oral hypoesthesia, dose: Initial: Buccal:
Maintenance Naloxone: glossodynia Buprenorphine 2.1
treatment of opioid 2-12 hours Orthostatic mg/naloxone 0.3 mg; may
dependence CYP450: hypotension repeat dose after 2 hours,
Maintenance CYP3A4 Implant specific: based on control of acute
treatment of opioid insertion site pain, withdrawal symptoms;
dependence in pruritis, erythema maximum total dose:
patients who have Respiratory buprenorphine 4.2
achieved and depression mg/naloxone 0.7 mg.
sustainced prolonged Hepatotoxicity Day 2: induction dose: Up
clinical stability on to buprenorphine 8.4
low-to-moderate mg/naloxone 1.4 mg as a
doses of a single dose.
transmucosal Suboxone:
buprenorphine- Day 1: induction
containing product dose: Initial: Sublingual:
Moderate to severe Buprenorphine 2
opioid use disorder mg/naloxone 0.5 mg or
in patients who have buprenorphine 4
initiated treatment mg/naloxone 1 mg; may
with a transmucosal titrate dose, based on
buprenorphine- control of acute
containing product, withdrawal symptoms, in
followed by dose buprenorphine 2
adjustment for a mg/naloxone 0.5 mg or
minimum of 7 days buprenorphine 4
Addiction_Medication_Table.docx.pdfAddiction_Medication_Table.docx.pdf!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!######################################
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!#######################Addiction_Medication_Table.docx.pdfAddiction_Medication_Table.docx.pdf!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Addiction_Medication_Table.docx.pdf!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!#######################Addiction_Medication_Table.docx.pdfAddiction_Medicat
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!#######################Addiction_Medication_Table.docx.pdfAddiction_Medication_Table.docx.pdf!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Addiction_Medication_Table.docx.pdf!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!#######################Addiction_Medication_Table.docx.pdfAddiction_Medicat
Darah Cummins
Drug Name Indication Half-life Notable Side Effects (link Initial Dosing
Neurotransmitter(s) Affected (T1/2), to NT or affected brain Considerations
Target Symptoms Metabolis circuit) Specific lifespan
m (CYP 450 considerations (age,
enzyme) pregnancy, breastfeeding)
Buprenorphine Indication: Half-life: Headache, Initial dosing:
(Subutex) Maintenance 24-42 constipation, Day 1: 8 mg
treatment of opioid hours nausea Day 2: 12-16 mg
dependence CYP450: Oral hypoesthesia, Days 3-7: Increase in
Maintenance CYP3A4 glossodynia increments of 4 mg,
treatment of opioid Orthostatic maximum 32 mg
dependence in hypotension Considerations:
patients who have Implant specific: Use with caution
achieved and insertion site pain, in elderly and
sustainced prolonged pruritis, erythema those with cardiac
clinical stability on Respiratory impairment
low-to-moderate depression May be
doses of a Hepatotoxicity preferable to
transmucosal methadone in
buprenorphine- pregnant women
containing product Neonatal
Moderate to severe withdrawal may
opioid use disorder occur
in patients who have Drug is found in
initiated treatment breast milk,
with a transmucosal recommended to
buprenorphine- DC drug or bottle
containing product, feed
followed by dose Safety and
adjustment for a efficacy has not
minimum of 7 days been established
Neurotransmitters: for children and
Mu opioid receptor adolescents
partial agonist
Addiction_Medication_Table.docx.pdfAddiction_Medication_Table.docx.pdf!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!######################################
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!#######################Addiction_Medication_Table.docx.pdfAddiction_Medication_Table.docx.pdf!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Addiction_Medication_Table.docx.pdf!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!#######################Addiction_Medication_Table.docx.pdfAddiction_Medicat
,Addiction_Medication_Table.docx.pdfAddiction_Medication_Table.docx.pdf!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!######################################
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!#######################Addiction_Medication_Table.docx.pdfAddiction_Medication_Table.docx.pdf!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Addiction_Medication_Table.docx.pdf!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!#######################Addiction_Medication_Table.docx.pdfAddiction_Medicat
Darah Cummins
Antagonist at the
kappa opioid
receptor
Target symptoms:
Opioid dependence
Buprenorphine/Naloxone Indication: Half-life: Headache, Initial dosing:
(Suboxone, Zubsolv, Induction of Suboxone: constipation, Bunavail:
Bunavail) treatment for opoid 24-42 nausea Day 1: induction
dependence hours Oral hypoesthesia, dose: Initial: Buccal:
Maintenance Naloxone: glossodynia Buprenorphine 2.1
treatment of opioid 2-12 hours Orthostatic mg/naloxone 0.3 mg; may
dependence CYP450: hypotension repeat dose after 2 hours,
Maintenance CYP3A4 Implant specific: based on control of acute
treatment of opioid insertion site pain, withdrawal symptoms;
dependence in pruritis, erythema maximum total dose:
patients who have Respiratory buprenorphine 4.2
achieved and depression mg/naloxone 0.7 mg.
sustainced prolonged Hepatotoxicity Day 2: induction dose: Up
clinical stability on to buprenorphine 8.4
low-to-moderate mg/naloxone 1.4 mg as a
doses of a single dose.
transmucosal Suboxone:
buprenorphine- Day 1: induction
containing product dose: Initial: Sublingual:
Moderate to severe Buprenorphine 2
opioid use disorder mg/naloxone 0.5 mg or
in patients who have buprenorphine 4
initiated treatment mg/naloxone 1 mg; may
with a transmucosal titrate dose, based on
buprenorphine- control of acute
containing product, withdrawal symptoms, in
followed by dose buprenorphine 2
adjustment for a mg/naloxone 0.5 mg or
minimum of 7 days buprenorphine 4
Addiction_Medication_Table.docx.pdfAddiction_Medication_Table.docx.pdf!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!######################################
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!#######################Addiction_Medication_Table.docx.pdfAddiction_Medication_Table.docx.pdf!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Addiction_Medication_Table.docx.pdf!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!#######################Addiction_Medication_Table.docx.pdfAddiction_Medicat
